SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior authorization at Humana
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Humana requires GLP-1 Receptor Agonist prior-authorization documentation for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Humana reviews SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior authorizations against its medical policy for GLP-1 Receptor Agonist. Humana-specific context: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in GLP-1 Receptor Agonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Humana's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Weight-loss exclusion (Wegovy)
- Step therapy requiring oral semaglutide before injectable
- BMI threshold above FDA label
- Non-formulary tier 4 specialty
Sold as Ozempic (T2D), Wegovy (weight loss + CV risk reduction), Rybelsus (oral T2D). Wegovy received FDA CV indication March 2024 based on SELECT trial.
Manufacturer patient-assistance program: NovoCare — relevant when a Humana denial sticks and the patient needs bridge access while appealing.
How Humana approaches GLP-1 receptor agonists PAs
For SEMAGLUTIDE (WEGOVY), check whether the current Humana GLP-1 receptor agonists policy cites ma plan step therapy on part b drugs or prior auth on specialty drugs. Pharmacy-benefit review for SEMAGLUTIDE (WEGOVY) at Humana is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Humana; if denied, use the filing date and route printed on that denial notice. The current Humana policy may distinguish T2D-indication PAs (Ozempic, Mounjaro, Trulicity) from weight-management-indication PAs (Wegovy, Zepbound, Saxenda); verify any benefit-exclusion language in the member product. Humana is domiciled in KY, so unresolved appeals escalate to the KY insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.humana.com/provider) with the same packet plus an applicable, current clinical source supporting SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus)for the patient's indication.
Medicare Advantage cases may have plan reconsideration and independent-review steps. Confirm the current level, forwarding rule, and any expedited pathway directly in the notice before selecting an escalation route.
Humana Medicare Advantage organization determinations operate under 42 CFR Part 422 Subpart D. For SEMAGLUTIDE (WEGOVY), the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. The applicable decision period and any Independent Review Entity routing depend on the request type, current rule, and plan notice. Record the cited source and version, then verify the operational due date against the current notice and CMS materials before relying on it.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Humana denial on DenialHelp.
Contact Humana
- Provider portal: https://www.humana.com/provider
Frequently asked questions
What documentation does Humana need for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior auth?
Humana's typical PA packet for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For GLP-1 Receptor Agonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Humana?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) at Humana?
Preparation scenarios to check against the current notice and policy include: MA plan step therapy on Part B drugs; Skilled nursing facility days; Prior auth on specialty drugs. These are not measured frequency claims. For SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Why does Humana require specific BMI documentation for SEMAGLUTIDE (WEGOVY)?
Humana's GLP-1 prior-auth policy distinguishes T2D-indication submissions (A1C-based criteria) from weight-management-indication submissions (BMI ≥30, or ≥27 with weight-related comorbidity, matching the FDA label). For weight-management SEMAGLUTIDE (WEGOVY) the reviewer also screens for the plan's anti-obesity-medication exclusion — submit the chart note with BMI, weight-related comorbidity (HTN, dyslipidemia, T2D, OSA, OA), and either (a) documented lifestyle intervention or (b) a documented reason intensive lifestyle was inappropriate. Verify current criteria and timing in the member-specific payer source. Pharmacy-benefit handling is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). External-review escalation for Humana fully-insured policies sits with the KY insurance department.
How do I prep for a peer-to-peer with Humana on SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) PA packet
Open ApprovalHelp — generate a SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior-auth packet tailored to Humana's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com